Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c02068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Mattias F Lindberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France. Hauptthemen laut MEDLINE: Protein Kinases, Protein Processing, Post-Translational. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 177 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, European Innovation Council, Fonds Unique Interministériel.
Abstract (Originalsprache)
Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) play a large variety of cellular functions and are involved in several diseases (cognitive disorders, diabetes, cancers, etc.). There is, thus, growing interest in pharmacological inhibitors as chemical probes and potential drug candidates. This study presents an unbiased evaluation of the kinase inhibitory activity of a library of 56 reported DYRK/CLK inhibitors on the basis of comparative, side-by-side, catalytic activity assays on a panel of 12 recombinant human kinases, enzyme kinetics (residence time and Kd), in-cell inhibition of Thr-212-Tau phosphorylation, and cytotoxicity. The 26 most active inhibitors were modeled in the crystal structure of DYRK1A. The results show a rather large diversity of potencies and selectivities among the reported inhibitors and emphasize the difficulties to avoid "off-targets" in this area of the kinome. The use of a panel of DYRKs/CLKs inhibitors is suggested to analyze the functions of these kinases in cellular processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France.
- Oncodesign, 25-27 avenue du Québec, 91140 Villebon-sur-Yvette, France.
- Enzymlogic, Qube Technology Park, C/Santiago Grisolía, 2, 28760 Madrid, Spain.
ORCID-Profile: Mattias F Lindberg, Laurent Meijer
Förderung
- Agence Nationale de la Recherche
- European Innovation Council
- Fonds Unique Interministériel
- Horizon 2020 Framework Programme
- Fondation Jérôme Lejeune
Zitieren
APA
Lindberg, M. F., Deau, E., Arfwedson, J., George, N., George, P., Alfonso, P., Corrionero, A., & Meijer, L. (2023). Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c02068
Vancouver
Lindberg MF, Deau E, Arfwedson J, George N, George P, Alfonso P, et al. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c02068
BibTeX
@article{Lindberg2023,
author = {Lindberg, Mattias F and Deau, Emmanuel and Arfwedson, Jonas and George, Nicolas and George, Pascal and Alfonso, Patricia and Corrionero, Ana and Meijer, Laurent},
title = {Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c02068}
}
EUVIMED